Macrophage Migration Inhibitory Factor Is Detrimental in Pneumococcal Pneumonia and a Target for Therapeutic
Jeffrey N Weiser1, Aoife M Roche1, Christopher B Hergott2
1Department of Microbiology.
Abstract:
Mortality from pneumococcal pneumonia remains high despite antibiotic therapy, highlighting the pathogenic potential for host inflammation. We demonstrate that macrophage migration inhibitory factor (MIF), an innate immune mediator, is detrimental for survival and associated with lung pathology, inflammatory cellular infiltration, and bacterial replication in a mouse model of pneumococcal pneumonia, despite being necessary for clearance from the nasopharynx. Treatment of animals with a small-molecule inhibitor of MIF improves survival by reducing inflammation and improving bacterial control. Our work demonstrates that MIF modulates beneficial versus detrimental inflammatory responses in the host-pneumococcal interaction and is a potential target for therapeutic modulation.
Insights
Macrophage migration inhibitory factor (MIF) worsens pneumococcal pneumonia by increasing inflammation and bacterial growth. Inhibiting MIF improves survival, offering a new therapeutic target for this serious lung infection.
Area of Science:
- Immunology
- Infectious Diseases
- Microbiology
Background:
- Pneumococcal pneumonia mortality remains high despite antibiotics.
- Host inflammatory responses contribute to disease severity.
- The role of innate immune mediators in pneumococcal pneumonia is not fully understood.
Purpose of the Study:
- To investigate the role of macrophage migration inhibitory factor (MIF) in pneumococcal pneumonia pathogenesis.
- To evaluate the therapeutic potential of targeting MIF in a mouse model.
Main Methods:
- Utilized a mouse model of Streptococcus pneumoniae infection.
- Assessed the impact of MIF on lung pathology, inflammation, and bacterial load.
- Administered a small-molecule MIF inhibitor to treated animals.
Main Results:
- MIF was associated with increased lung pathology, inflammation, and bacterial replication.
- MIF was necessary for bacterial clearance from the nasopharynx but detrimental in the lungs.
- MIF inhibition significantly improved survival by reducing inflammation and controlling bacterial growth.
Conclusions:
- MIF plays a dual role in pneumococcal pneumonia, being beneficial for nasopharyngeal clearance but detrimental in the lungs.
- Targeting MIF with small-molecule inhibitors represents a promising therapeutic strategy to improve outcomes in pneumococcal pneumonia.
More Related Videos
11:32Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
Published on: February 23, 2014
10:35Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation
Published on: December 26, 2017